Dysautonomia in anti-Hu paraneoplastic neurological syndromes.
ANNA-1
Autonomic function
Dysautonomia
Hu
Paraneoplastic autoimmunity
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
17 Mar 2024
17 Mar 2024
Historique:
received:
15
01
2024
accepted:
25
02
2024
revised:
23
02
2024
medline:
18
3
2024
pubmed:
18
3
2024
entrez:
18
3
2024
Statut:
aheadofprint
Résumé
Dysautonomia has been associated with paraneoplastic neurological syndrome (PNS)-related mortality in anti-Hu PNS, but its frequency and spectrum remain ill-defined. We describe anti-Hu patients with dysautonomia, estimate its frequency, and compare them to patients without dysautonomia. Patients with anti-Hu antibodies diagnosed in the study centre (1990-2022) were retrospectively reviewed; those with autonomic signs and symptoms were identified. Among 477 anti-Hu patients, 126 (26%) had dysautonomia (the only PNS manifestation in 7/126, 6%); gastrointestinal (82/126, 65%), cardiovascular (64/126, 51%), urogenital (24/126, 19%), pupillomotor/secretomotor (each, 11/126, 9%), and central hypoventilation (10/126, 8%). Patients with isolated CNS involvement less frequently had gastrointestinal dysautonomia than those with peripheral (alone or combined with CNS) involvement (7/23, 30% vs. 31/44, 70% vs. 37/52, 71%; P = 0.002); while more frequently central hypoventilation (7/23, 30% vs. 1/44, 2.3% vs. 2/52, 4%; P < 0.001) and/or cardiovascular alterations (18/23, 78% vs. 20/44, 45% vs. 26/52, 50%; P = 0.055). Median [95% CI] overall survival was not significantly different between patients with (37 [17; 91] months) or without dysautonomia (28 [22; 39] months; P = 0.78). Cardiovascular dysautonomia (HR: 1.57, 95% CI [1.05; 2.36]; P = 0.030) and central hypoventilation (HR: 3.51, 95% CI [1.54; 8.01]; P = 0.003) were associated with a higher risk of death, and secretomotor dysautonomia a lower risk (HR: 0.28, 95% CI [0.09; 0.89]; P = 0.032). Patients with cardiovascular dysautonomia dying ≤ 1 year from clinical onset had severe CNS (21/27, 78%), frequently brainstem (13/27, 48%), involvement. Anti-Hu PNS dysautonomia is rarely isolated, frequently gastrointestinal, cardiovascular and urogenital. CNS dysfunction, particularly brainstem, associates with lethal cardiovascular alterations and central hypoventilation, while peripheral involvement preferentially associates with gastrointestinal or secretomotor dysautonomia, being the latest more indolent.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Dysautonomia has been associated with paraneoplastic neurological syndrome (PNS)-related mortality in anti-Hu PNS, but its frequency and spectrum remain ill-defined. We describe anti-Hu patients with dysautonomia, estimate its frequency, and compare them to patients without dysautonomia.
METHODS
METHODS
Patients with anti-Hu antibodies diagnosed in the study centre (1990-2022) were retrospectively reviewed; those with autonomic signs and symptoms were identified.
RESULTS
RESULTS
Among 477 anti-Hu patients, 126 (26%) had dysautonomia (the only PNS manifestation in 7/126, 6%); gastrointestinal (82/126, 65%), cardiovascular (64/126, 51%), urogenital (24/126, 19%), pupillomotor/secretomotor (each, 11/126, 9%), and central hypoventilation (10/126, 8%). Patients with isolated CNS involvement less frequently had gastrointestinal dysautonomia than those with peripheral (alone or combined with CNS) involvement (7/23, 30% vs. 31/44, 70% vs. 37/52, 71%; P = 0.002); while more frequently central hypoventilation (7/23, 30% vs. 1/44, 2.3% vs. 2/52, 4%; P < 0.001) and/or cardiovascular alterations (18/23, 78% vs. 20/44, 45% vs. 26/52, 50%; P = 0.055). Median [95% CI] overall survival was not significantly different between patients with (37 [17; 91] months) or without dysautonomia (28 [22; 39] months; P = 0.78). Cardiovascular dysautonomia (HR: 1.57, 95% CI [1.05; 2.36]; P = 0.030) and central hypoventilation (HR: 3.51, 95% CI [1.54; 8.01]; P = 0.003) were associated with a higher risk of death, and secretomotor dysautonomia a lower risk (HR: 0.28, 95% CI [0.09; 0.89]; P = 0.032). Patients with cardiovascular dysautonomia dying ≤ 1 year from clinical onset had severe CNS (21/27, 78%), frequently brainstem (13/27, 48%), involvement.
DISCUSSION
CONCLUSIONS
Anti-Hu PNS dysautonomia is rarely isolated, frequently gastrointestinal, cardiovascular and urogenital. CNS dysfunction, particularly brainstem, associates with lethal cardiovascular alterations and central hypoventilation, while peripheral involvement preferentially associates with gastrointestinal or secretomotor dysautonomia, being the latest more indolent.
Identifiants
pubmed: 38494470
doi: 10.1007/s00415-024-12278-4
pii: 10.1007/s00415-024-12278-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-18-RHUS-0012
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Vernino S (2020) Autoimmune autonomic disorders. Continuum: Lifelong Learn Neurol 26:44–57. https://doi.org/10.1212/CON.0000000000000812
doi: 10.1212/CON.0000000000000812
Hébert J, Riche B, Vogrig A et al (2020) Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm 7(6):e883. https://doi.org/10.1212/NXI.0000000000000883
doi: 10.1212/NXI.0000000000000883
pubmed: 32847939
pmcid: 7455315
Vogrig A, Gigli GL, Segatti S et al (2020) Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol 267(1):26–35. https://doi.org/10.1007/s00415-019-09544-1
doi: 10.1007/s00415-019-09544-1
pubmed: 31552550
Dalmau J, Graus F, Rosenblum MK, Posner JB (1992) Anti-Hu–associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 71(2):59–72. https://doi.org/10.1097/00005792-199203000-00001
doi: 10.1097/00005792-199203000-00001
pubmed: 1312211
Graus F, Keime-Guibert F, Reñe R et al (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124(Pt 6):1138–1148. https://doi.org/10.1093/brain/124.6.1138
doi: 10.1093/brain/124.6.1138
pubmed: 11353730
Lucchinetti CF, Kimmel DW, Lennon VA (1998) Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 50(3):652–657. https://doi.org/10.1212/wnl.50.3.652
doi: 10.1212/wnl.50.3.652
pubmed: 9521251
Sillevis Smitt P, Grefkens J, de Leeuw B et al (2002) Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 249(6):745–753. https://doi.org/10.1007/s00415-002-0706-4
doi: 10.1007/s00415-002-0706-4
pubmed: 12111309
Villagrán-García M, Farina A, Muñiz-Castrillo S et al (2023) Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis. Brain Commun 5(5):fcad247. https://doi.org/10.1093/braincomms/fcad247
doi: 10.1093/braincomms/fcad247
pubmed: 37794924
pmcid: 10546956
Graus F, Vogrig A, Muñiz-Castrillo S et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8(4):e1014. https://doi.org/10.1212/NXI.0000000000001014
doi: 10.1212/NXI.0000000000001014
pubmed: 34006622
pmcid: 8237398
Giometto B (2010) Paraneoplastic neurologic syndrome in the PNS euronetwork database: a European Study from 20 centers. Arch Neurol 67(3):330. https://doi.org/10.1001/archneurol.2009.341
doi: 10.1001/archneurol.2009.341
pubmed: 20212230
Saiz A, Bruna J, Stourac P et al (2009) Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry 80(4):404–407. https://doi.org/10.1136/jnnp.2008.158246
doi: 10.1136/jnnp.2008.158246
pubmed: 19015226
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5):604–607. https://doi.org/10.1161/01.str.19.5.604
doi: 10.1161/01.str.19.5.604
pubmed: 3363593
R: The R Project for Statistical Computing. https://www.r-project.org/ . Accessed 8 Jan 2024
Tobin WO, Lennon VA, Komorowski L et al (2014) DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 83(20):1797–1803. https://doi.org/10.1212/WNL.0000000000000991
doi: 10.1212/WNL.0000000000000991
pubmed: 25320100
pmcid: 4240433
Manley GT, Smitt PS, Dalmau J, Posner JB (1995) Hu antigens: reactivity with hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 38(1):102–110. https://doi.org/10.1002/ana.410380117
doi: 10.1002/ana.410380117
pubmed: 7541976
ELAVL2 protein expression summary - The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000107105-ELAVL2 . Accessed 9 Oct 2023
ELAVL3 protein expression summary - The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000196361-ELAVL3 . Accessed 9 Oct 2023
ELAVL4 protein expression summary - The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000162374-ELAVL4 . Accessed 9 Oct 2023
Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB (1991) Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology 41(11):1757–1757. https://doi.org/10.1212/WNL.41.11.1757
doi: 10.1212/WNL.41.11.1757
pubmed: 1944905
Benarroch EE (2020) Physiology and pathophysiology of the autonomic nervous system. Continuum: Lifelong Learn Neurol 26(1):12–24. https://doi.org/10.1212/CON.0000000000000817
doi: 10.1212/CON.0000000000000817
de Montmollin E, Demeret S, Brulé N et al (2017) Anti-N-methyl-d-aspartate receptor encephalitis in adult patients requiring intensive care. Am J Respir Crit Care Med 195(4):491–499. https://doi.org/10.1164/rccm.201603-0507OC
doi: 10.1164/rccm.201603-0507OC
pubmed: 27552490
Yan L, Zhang S, Huang X, Tang Y, Wu J (2021) Clinical study of autonomic dysfunction in patients with anti-NMDA receptor encephalitis. Front Neurol 12:609750. https://doi.org/10.3389/fneur.2021.609750
doi: 10.3389/fneur.2021.609750
pubmed: 33613429
pmcid: 7894204
Zhao-Fleming HH, Zahid A, Lu T et al (2022) Characterization of cardiac bradyarrhythmia associated with LGI1-IgG autoimmune encephalitis. Front Immunol 13:948479. https://doi.org/10.3389/fimmu.2022.948479
doi: 10.3389/fimmu.2022.948479
pubmed: 36304459
pmcid: 9592974
Heath JP, Ewing DJ, Cull RE (1988) Abnormalities of autonomic function in the Lambert Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 51(3):436–439. https://doi.org/10.1136/jnnp.51.3.436
doi: 10.1136/jnnp.51.3.436
pubmed: 3361337
pmcid: 1032876
Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W (2012) COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc 87(12):1196–1201. https://doi.org/10.1016/j.mayocp.2012.10.013
doi: 10.1016/j.mayocp.2012.10.013
pubmed: 23218087
pmcid: 3541923
Chow KE, Dhyani R, Chelimsky TC (2021) Basic tests of autonomic function. J Clin Neurophysiol 38(4):252–261. https://doi.org/10.1097/WNP.0000000000000789
doi: 10.1097/WNP.0000000000000789
pubmed: 34009852
Grüter T, Möllers FE, Tietz A et al (2022) Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease. Brain. https://doi.org/10.1093/brain/awac090
doi: 10.1093/brain/awac090
pmcid: 10151189
Foldvary-Schaefer NR, Waters TE (2017) Sleep-disordered breathing. Continuum: Lifelong Learn Neurol 23(4):1093–1116. https://doi.org/10.1212/01.CON.0000522245.13784.f6
doi: 10.1212/01.CON.0000522245.13784.f6
Lladó A, Carpentier AF, Honnorat J et al (2006) Hu-antibody-positive patients with or without cancer have similar clinical profiles. J Neurol Neurosurg Psychiatry 77(8):996–997. https://doi.org/10.1136/jnnp.2005.085753
doi: 10.1136/jnnp.2005.085753
pubmed: 16844961
pmcid: 2077609